Cardiovascular therapeutic applications

Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition

Volumn , Issue , 2007, Pages 601-639

  Crooke, Rosanne ^a   Baker, Brenda ^a   Wedel, Mark ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84860620193     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (226)

1. Lloyd-Jones, D.M. et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age, Circulation, 113, 791, 2006.
2. Epstein, J.A., Rader, D.J., and Parmacek, M.S. Perspective: cardiovascular disease in the postgenomic era-Lessons learned and challenges ahead, Endocrinology, 143, 2045, 2002.
3. Davis, R.A. and Hui, T.Y. 2000 George Lyman Duff memorial lecture. Atherosclerosis is a liver disease of the heart, Arterioscler. Thromb. Vasc. Biol., 21, 887, 2001.
4. Nabel, E.G., Cardiovascular disease, N. Engl. J. Med., 349, 60, 2003.
5. World Health Organization Website. World Health Organization cardiovascular disease (CVD):prevention and control fact sheet 2003. http://www.who.int/dietphysicalactivity/publications/facts/cvd/en
6. Murray, C.J.L., and Lopez, A.D. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study, Lancet, 349, 1498, 1997.
7. Mahley, R.W. and Bersot, T.P. Drug therapy for hypercholesterolemia and dyslipidemia, in Goodman and Gilman’s The Pharmacological Basis of Therapeutics, Brunton L.L., ed., McGraw-Hill, NewYork, 2006, chap. 35.
8. Grundy, S.M. et al. Assessment of cardiovascular risk by use of multiple risk factor assessment equations. A statement for Healthcare professional from the American Heart Association and the American College of Cardiology, J. Am. Coll. Cardiol., 34, 1348, 1999.
9. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults, JAMA, 285, 2486, 2001.
10. Grundy, S.M. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, Circulation, 110, 227, 2004.
11. Knopp, R.H. Drug treatment of lipid disorders, N. Engl. J. Med., 341, 498, 1999.
12. Lipid Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N. Engl. J. Med., 339, 1339, 1998.
13. Downs, G.R., Clearfield, M., and Weiss, S. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of the AFCAPS/TEXCAPS (Air Forces/Texas Coronary Atherosclerosis Prevention Study), JAMA, 279, 1615, 1998.
14. Heart Protection Study Collaborative Group: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo controlled trial, Lancet, 360, 7, 2002.
15. Hulthe, J. and Faberberg, B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study), Arterioscler. Thromb. Vasc. Biol. 22, 1162, 2002.
16. Skalen, K. et al. Subdendothelial retention of atherogenic lipoproteins in early atherosclerosis, Nature, 417, 750, 2002.
17. Cholesterol Treatment Trialists (CTT) Collaborators, Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet, 366, 1267, 2005.
18. Nissen, S.E. et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial, JAMA, 291, 1071, 2004.
19. Nissen, S.E., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial, JAMA, 295, 1556, 2006.
20. Gotto, A.M. Management of dyslipidemia, Am. J. Med., 112, 102, 2002.
21. Abookire, S. A. et al. Use and monitoring of statin lipid-lowering drugs compared with guidelines, Arch. Int. Med., 161, 53, 2001.
22. Ahmed, S.M., Clasen, M.E., and Donnelly, J.E. Management of dyslipidemia in adults, Am. Fam. Physician, 57, 2192, 1998.
23. Bocan, T.M. Pleiotropic effects of HMG-CoA reductase inhibitors, Curr. Opin. Invest. Drugs, 2, 21, 2002.
24. Grundy, S.M. et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement, Circulation, 112, 2735, 2005.
25. Lewis, G.F. and Rader, D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport, Circ. Res., 96, 1221, 2005.
26. Nicholls, S.J. and Nissen, S.E. Strategies to promote HDL-C: an emerging therapeutic target, Eur. Heart. J., 26, 853, 2005.
27. Carlson, L.A., Hamsten, A., and Asplund, A. Pronounced lowering of serum lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid, J. Intern. Med., 226, 271, 1989.
28. Utermann, G. Lipoprotein(a), in The Metabolic & Molecular Bases of Inherited Disease, Scriver, C.R., Beaudet, A.L., Sly, W.S., and Valle, D., eds., McGraw-Hill, New York, 2001, chap. 116.
29. Pearson, T.A. et al. The Lipid Treatment Assessment Project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving lowdensity lipoprotein cholesterol goals, Arch. Inter. Med., 160, 459, 2000.
30. Jacobsen, T.A. et al. Impact of evidence-based “clinical judgement” on the number of American adults requiring lipid-lowering therapy based on updated NHANES III Data, Arch. Inter. Med., 160, 1361, 2000.
31. Sloan, K.L. et al. Frequency of serum low-density lipoprotein cholesterol measurement and frequency of results ≥100 mg/dl among patients who had coronary events (Northwest VA Network Study), Am. J. Cardiol., 88, 1143, 2001.
32. Sueta, C.A. et al. Undertreatment of hyperlipidemia in patients with coronary artery disease and heart failure, J. Cardiac Failure, 9, 36, 2003.
33. Stein, E. et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia:efficacy and safety of Ezetimibe co-administered with atorvastatin, Am. Heart J., 148, 447, 2004.
34. Bruckert, E. et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study, Cardiovasc. Drugs Ther., 19, 403, 2005.
35. Levin, A.A. et al., Toxicity of antisense oligonucleotides, in Antisense Drug Technology. Principles, Strategies, and Applications, Crooke, S.T., ed., Marcel Dekker, Inc., New York, 2001, chap. 9.
36. Pacheo, G. et al. Characterization of nonspecific effects of phosphorothioate antisense oligodeoxynucleotides on cytochrome P450 3A2 and cytochrome P450 2CII in male Sprague-Dawley rats, Toxicologist, 66, 22, 2002.
37. Gonzalez, F.J. and Tukey, R.H. Drug metabolism, in Goodman and Gilman’s The Pharmacological Basis of Therapeutics, Brunton L.L., ed., McGraw-Hill, New York, 2006, chap 3.
38. Henry, S.P. et al. Drug properties of second generation antisense oligonucleotides: how do they measure up to their predecessors? Curr. Opin. Invest. Drugs, 2, 1444, 2001.
39. Geary, R.S. et al. Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotides in rat, J. Pharmacol. Exp. Ther., 296, 890, 2001.
40. Geary, R.S. et al. Pharmacokinetic properties in animals, in Antisense Drug Technology. Principles, Strategies, and Applications, Crooke, S.T., ed., Marcel Dekker, Inc., New York, 2001, chap. 6.
41. Yu, R. et al. Tissue disposition of 2′-O-(2-methoxy)ethyl modified antisense oligonucleotides in monkeys, J. Pharm. Sci., 93, 48, 2004.
42. Crooke, R.M., unpublished data, 2006.
43. Faxon, D.P. et al. Atherosclerotic vascular disease conference. Writing group III: pathophysiology, Circulation, 109, 2617, 2004.
44. Libby, P. and Theroux, P. Pathophysiology of coronary artery disease, Circulation, 111, 3481, 2005.
45. Deguchi, J.O. et al. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo, Circulation, 114, 55, 2006.
46. Tardif, J.C. et al. Vascular markers and surrogates in cardiovascular disease, Circulation, 113, 2936, 2006.
47. Graham, M.J. et al. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration, J. Pharmacol. Exp. Ther., 286, 447, 1998.
48. Graham, M.J. et al. Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration, Biochem. Pharmcol., 62, 297, 2001.
49. Zhang, H.J. et al. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis, Nat. Biotech., 18, 862, 2000.
50. Hoffman, B.B. Therapy of hypertension, in Goodman and Gilman’s The Pharmacological Basis of Therapeutics, Brunton L.L., ed., McGraw-Hill, New York, 2006, chap. 32.
51. Browning, J.D. and Horton, J.D. Molecular mediators of hepatic steatosis and liver injury, J. Clin. Invest., 114, 147, 2004.
52. Linsel-Nitschke, P. and Tall, A.R. HDL as a target in the treatment of atherosclerotic cardiovascular disease, Nat. Rev. Drug Discov., 4, 193, 2005.
53. Tall, A.R. Plasma cholesteryl ester transfer protein, J. Lipid. Res., 34, 1255, 1993.
54. Doggrell, S.A. Inhibitors of cholesteryl ester transfer protein-a new approach to coronary artery disease, Expert Opin. Investig. Drugs, 15, 99, 2006.
55. Bruce, C., Sharpe, D.S., and Tall, A.R. Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyderidemia, J. Lipid. Res., 39, 1071, 1998.
56. Clark, R.W. et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib, Arterioscler. Thromb. Vasc. Biol., 24, 490, 2004.
57. Clark, R.W. Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors, Curr. Opin. Pharmacol., 6, 162, 2006.
58. Sugano, M. and Makino, N. Changes in plasma lipoprotein cholesterol levels by antisense oligodeoxynucleotides against cholesteryl ester transfer protein in cholesterol-fed rabbits, J. Biol. Chem., 271, 19,080, 1996.
59. Sugano, M. et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits, J. Biol. Chem., 2731, 5033, 1998.
60. Chiou, H.C. et al. Enchanced resistance to nuclease degradation of nucleic acids complexed to asialoglycoprotein-polylysine carriers, Nucl. Acids Res., 22, 5439, 1994.
61. Anke, H.E.M. et al. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels. Pathways by which modulation of CETP activity may alter atherogenesis, Arterioscler. Thromb. Vasc. Biol., 25, 2020, 2005.
62. Crooke, R.M., personal communication, 2006.
63. Berg, K. A new serum type system in man-the Lp system, Acta Path. Microbiol. Scand., 59, 369, 1963.
64. Berglund, L. and Ramakrishnan, R. Lipoprotein(a). An elusive cardiovascular risk factor, Arterioscler. Thromb. Vasc. Biol., 24, 2219, 2004.
65. Berg, K. et al. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study, Clin. Genet., 52, 254, 1997.
66. Candido, A.P. et al. Lipoprotein(a) as a risk factor associated with ischemic heart disease: Ouro Preto Study, Atherosclerosis, in press, 2006.
67. Schreiner, P.J. et al. Lipoprotein(a) as a risk factor for preclinical atherosclerosis, Arterioscler. Thromb., 13, 826, 1993.
68. Edelstein, C. et al. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a), J. Biol. Chem., 278, 52,841, 2003.
69. Silaste, M.I. et al. Changes in dietary fat alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a), Arterioscler. Thromb. Vasc. Biol., 24, 498, 2004.
70. Tsimikas, S. et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes, J. Am. Coll. Cardiol., 41, 360, 2003.
71. Schneider, M. et al. High-level lipoprotein(a) expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein(a) but not in low density lipoproteins, J. Lipid. Res., 46, 769, 2005.
72. Rath, M. et al. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients, Arteriosclerosis, 9, 579, 1989.
73. Cushing, G.L. et al. Quantitation and localization of apolipoproteins (a) and B in coronary artery bypass vein grafts resected at reoperation, Arteriosclerosis, 9, 593, 1989.
74. Schenck, I. et al. Reduction of Lp(a) by different methods of plasma exchange, Klin. Wochenschr., 66, 1197, 1988.
75. Eliassen, K. et al. Significant reduction of lipoprotein(a) level in LPA-transgenic mice after treatment with an antisense inhibitor of the LPA gene, Atherosclerosis, in press, 2006.
76. Berg, K. et al. Spontaneous atherosclerosis in the proximal aorta of LPA transgenic mice on a normal diet, Atherosclerosis, 163, 99, 2002.
77. Crooke, R.M., personal communication, 2006.
78. Asia Pacific Cohort Studies Collaboration, Serum triglycerides as a risk factor for cardiovascular disease in the Asia-Pacific Region, Circulation, 110, 2678, 2004.
79. Tanne, D. et al. Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Benzfibrate infarction prevention (BIP) registry. High triglycerides constitute an independent risk factor, Circulation, 104, 2892, 2001.
80. Schoonjans, K., Staels, B., and Auwerx, J. Role of the peroxisome proliferators-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression, Circulation, 37, 907, 1996.
81. Haubenwallner, S. et al. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action, J. Lipid. Res., 36, 2451,1995.
82. Staels, B. et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism, Circulation, 98, 2088,1998.
83. Minnich, A. et al. A potent PPARα agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle, Am. J. Physiol. Endocrinol. Metab., 280, E270, 2001.
84. Goldberg, I.J. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis, J. Lipid. Res., 37, 693, 1996.
85. Dallinga-Thie, G. et al. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoproteins and HDL in Type 2 diabetes, Diabetes Care, 27, 1358, 2004.
86. Maeda, N. et al. Targeted disruption of the apolipoprotein C-III genes in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia, J. Biol. Chem., 269, 23,610, 1994.
87. Ginsberg, H.N. et al. Apolipoprotein B metabolism in subjects with a deficiency of apolipoprotein CIII and A1. Evidence that apolipoprotein CIII inhibits the catabolism of triglyceride-rich lipoprotein lipase in vivo, J. Clin. Invest., 78, 1287, 1986.
88. Hokanson, J.E. et al. Susceptibility to type 1 diabetes is associated with apoCIII gene haplotypes, Diabetes, 55, 834, 2006.
89. Florez, H. et al. Increased apolipoprotein C-III levels associated with insulin resistance contribute to dyslipidemia in normoglycemic and diabetic subjects from a triethnic population, Atherosclerosis, 188, 143, 2006.
90. 2-dependent beta cell death in type I diabetes, Proc. Natl. Acad. Sci. USA, 101, 19,909, 2004.
91. Chen, M. et al. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels, J. Lipid. Res., 35, 1918, 1994.
92. Altomonte, J. et al. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism, J. Clin. Invest., 114, 493, 2004.
93. Takahashi, T. et al. Apolipoprotein C-III deficiency prevents the development of hypertriglyceridemia in streptozotocin-induced diabetic mice, Metabolism, 52, 2354, 2003.
94. Gervaise, N. et al. Triglycerides, apoC3 and LpB: C3 and cardiovascular risk in type II diabetes, Diabetologia, 43, 703, 2000.
95. Tiret, I. et al. Postprandial response to a fat tolerance test in young adults with a paternal history of premature coronary artery disease; the EARS II study, Eur. J. Clin. Invest., 30, 578, 2000.
96. Subramaniam, A. et al. ApoC-III antisense oligonucleotides reduce liver mRNA and serum triglyceride levels in hypertriglyceridemic rats, Diabetes, 54, suppl.1, A233, 2005.
97. Lemonidis, K.M., unpublished data, 2006.
98. Rudel, L.L., Lee, R.G., and Parini, P. ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia, Arterioscler. Thromb. Vasc. Biol., 25, 1112, 2005.
99. Joyce, C. et al. Acyl-coenzyme A: cholesterol acyltransferase 2, Curr. Opin. Lipidol., 10, 89, 1999.
100. Parini, P. et al. ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver, Circulation, 110, 2017, 2004.
101. Chang, T.Y., Chang, C.C.Y., and Cheng, D. Acyl-coenzyme A: cholesterol acyl-transferase, Annu. Rev. Biochem., 66, 613, 1997.
102. Oelkers, P. et al. Characterization of two human genes encoding acyl coenzyme A: cholesterol acyltransferase-related enzymes, J. Biol. Chem., 273, 26,275, 1998.
103. Lee, R.G. et al. Differential expression of ACAT1 and ACAT2 among cells within the liver, intestine, kidney, and adrenal of nonhuman primate, J. Lipid. Res., 41, 1991, 2000.
104. Rudel, L.L., Lee, R.G., and Cockman, T.L. Acyl-coenzyme A: cholesterol acyltransferase type 1 and 2: structure and function in atherosclerosis, Curr. Opin. Lipidol., 12, 121, 2001.
105. Matsuo, M. et al. Effect of FR145237, a novel ACAT inhibitor, on atherogenesis in cholesterol-fed and WHHL rabbits. Evidence for a direct effect on the arterial wall. Biochem. Biophys. Acta., 1259, 254, 1995.
106. Accad, Â. et al. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA: cholesterol acyltransferase 1, J. Clin. Invest., 105, 711, 2000.
107. Yagyu, H. et al. Absence of ACAT1 attenuates atherosclerosis but causes dry eye and cutaneous xanthomatosis in mice with congenital hyperlipidemia, J. Biol. Chem., 275, 21,324, 2000.
108. Fazio, S. et al. Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages, J. Clin. Invest., 107, 163, 2001.
109. Warner, G.J. et al. Cell toxicity induced by inhibition of acyl coenzymeA: cholesterol acyltransferase and accumulation of unesterified cholesterol, J. Biol. Chem., 270, 5772, 1995.
110. Lee, R.G., et al. Plasma cholesteryl esters provided by lecithin:cholesterol acyltranferase and acyl-coenzyme A: cholesterol acyltransferase 2 have opposite atherosclerotic potential, Circ. Res., 95, 998, 2004.
111. Repa, J.J. et al. ACAT2 deficiency limits cholesterol absorption in cholesterol-fed mice: Impact on hepatic cholesterol homeostasis, Hepatology, 40, 1088, 2004.
112. Buhman, K.K. et al. Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice, Nat. Med., 6, 1341, 2000.
113. Willner, E.L. et al. Deficiency of acyl CoA: cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. USA, 100, 1262, 2003.
114. Farese, R.V. The nine lives of ACAT inhibitors. Arterioscler. Thromb. Vasc. Biol., 26,1684, 2006.
115. Sliskovic, D.R., Picard, J.A., and Krause, B.R. ACAT inhibitors: the search for a novel and effective treatment of hypercholesterolemia and atherosclerosis, Prog. Med. Chem., 39, 121, 2002.
116. Raal, F.J. et al. Avasimibe, and ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia, Atherosclerosis, 171, 273, 2003.
117. Tardif, J.-C. et al. Effects of the acyl coenzymeA: Cholesterol acyltransferase inhibitor Avasimibe on human atherosclerotic lesions, Circulation, 110, 3372, 2004.
118. Nissen, S.E. et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis, N. Engl. J. Med., 354, 1253, 2006.
119. -/- mice, Arterioscler. Thromb. Vasc. Biol., 26,1814, 2006.
120. Crooke, R.M. and Rudel, L.L., personal communication, 2006.
121. Crooke, R.M. et al. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis, J. Lipid Res., 46, 872, 2005.
122. Kastelein, J.J.P. et al. Potent reduction of apolipoprotein B and LDL cholesterol by short term administration of an antisense inhibitor of apolipoprotein B, Circulation, 114, 1729, 2006.
123. Greeve, J. Inhibition of the synthesis of apolipoproteinB-containing lipoproteins, HEP, 170, 483, 2005.
124. Davidson N.O. and Shelness G.S. Apolipoprotein B: mRNA editing, lipoprotein assembly, and presecretory degradation, Annu. Rev. Nutr., 20,169, 2000.
125. Marsh, J.B. et al. Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors, Atherosclerosis, 162, 227, 2002.
126. Olofsson, S.-O. and Boren, J. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis, J. Int. Med., 258, 395, 2005.
127. Oloffson, S.-V., Stillemark-Billton, P., and Asp, L. Intracellular assembly of VLDL. Two major steps in separate cell compartments, Trends Cardiovasc. Med., 10, 338, 2001.
128. Das, H.K., Leff, T., and Breslow, J.L., Cell type-specific expression of the human apoB gene is controlled by two cis-acting regulatory regions. J. Biol. Chem., 263, 11,452, 1998.
129. Anant, S. et al. Novel role for RNA-binding protein CUGBP2 in mammalian RNA editing, J. Biol. Chem., 276, 47,338, 2001.
130. Shoulder, C.C. and Shelness, G.S. Current biology of MTP; implications for selective inhibition, Curr. Topics Med. Chem., 5, 283, 2005.
131. Pease, R.J. and Leiper, J.M. Regulation of hepatic apolipoprotein-B-containing lipoprotein secretion, Curr. Opin. Lipidol., 7, 132, 1996.
132. Liang, J.-S. and Ginsberg, H. Microsomal triglyceride transfer protein binding and lipid transfer activities are independent of each other, but both are required for secretion of apolipoprotein B lipoproteins from liver cells, J. Biol. Chem., 276, 28,606, 2001.
133. Shelness, G.S. and Sellers, J. A. Very-low-density lipoprotein assembly and secretion, Curr. Opin. Lipidol., 12, 151, 2001.
134. Wang, S.-L. et al. Coordinate regulation of lipogenesis; the assembly and secretion of apolipoprotein B-containing lipoproteins by sterol response element binding protein 1, J. Biol. Chem., 272, 19,351, 1997.
135. Liang, J.-S. et al. Translocation efficiency, susceptibility to proteasomal degradation and lipid responsiveness of apolipoprotein B are determined by the presence of B sheet domains, J. Biol. Chem., 273, 35,216, 1998.
136. Kang, S. and Davis, R.A. Cholesterol and hepatic lipoprotein assembly and secretion, Biochem. Biophys. Acta, 1529, 223, 2000.
137. Fisher, E.A. et al. The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways, J. Biol. Chem., 276, 27,855, 2001.
138. Ginsberg, H. Insulin resistance and cardiovascular disease, J. Clin. Invest., 106, 453, 2000.
139. Chan, D.C. et al. Apolipoprotein B kinetics in visceral obesity; associations with plasma apolipoprotein C-III concentration, Metabolism, 51, 1041, 2002.
140. Kane, J.P. and Havel, R.J. Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins, in The Metabolic and Molecular Bases of Inherited Disease, Scriver, C.R. et al., eds., McGraw-Hill, New York, 2001, chap. 115.
141. Boren, J. et al. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apoB, J. Clin. Invest., 101, 1084, 1998.
142. Tybjaerg-Hansen, A. et al. Association of the mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease, N. Engl. J. Med., 338, 1577, 1998.
143. Gaffney, D. et al. Comparison of apolipoprotein B metabolism in familial defective apolipoprotein B and heterogeneous familial hypercholesterolemia, Atherosclerosis, 162, 33, 2002.
144. Greevenbroek, M.M.J., Vermeulen, V.M.M.-J, and deBruin, T.W.A. Familial combined hyperlipidemia plasma stimulates protein secretion by HepG2 cells: identification of fibronectin in the differential secretion proteome, J. Lipid Res., 43, 1846, 2002.
145. Veerkamp, M.J. et al. Diagnosis of familial combined hyperlipidemia based on lipid phenotypes expression in 32 families. Results of a 5 year follow-up study, Arterioscler. Thromb. Vasc. Biol., 22, 274, 2002.
146. Grundy, S.M. Hypertriglyderidemia, atherogenic dyslipidemia, and the metabolic syndrome, Am. J. Cardiol., 81, 18B, 1998.
147. Chan, D.C. et al. Regulatory effects of HMGCoA reductase inhibitot and fish oils on apolipoprotein B kinetics in insulin-resistant obese male subjects with dyslipidemia, Diabetes, 51, 2377, 2002.
148. Farese, R.V. et al. Knockout of the mouse apolipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes, Proc. Natl. Acad. Sci. USA, 92, 1774, 1995.
149. Srivastava, R.A. et al. Regulation of the apolipoprotein B in heterozygous hypobetalipoproteinemic knock-out mice expressing truncated apoB, B81. Low production and enhanced clearance of apoB cause low levels of apoB, Mol. Cell Biochem., 202, 37, 1999.
150. Liao, W., Young, S.G., and David, R. Blocking microsomal triglyceride transfer protein interferes with apolipoprotein B secretion without causing retention or stress in the endoplasmic reticulum, J. Lipid Res., 44, 978, 2003.
151. Lieu, H.D. et al. Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion, Circulation, 107, 1315, 2003.
152. Magnin, D.R. et al. Microsomal triglyceride transfer protein inhibitors: discovery and synthesis of alkyl phosphonates as potent MTP inhibitors and cholesterol lowering agents, Bioorg. Med. Chem. Lett., 13, 1337, 2003.
153. Leung, G.K. et al. A deficiency of microsomal triglyceride transfer protein reduced apolipoprotein B secretion, J. Biol. Chem., 275, 7515, 2000.
154. Yang, Y., Ballatori, N., and Smith, N.C. Apolipoprotein B mRNA editing and the reduction in synthesis and secretion of the atherogenic risk factor, apolipoprotein B100 can be effectively targeted through TAT-mediated protein transduction, Mol. Pharm., 61, 269, 2002.
155. Yamanaka, S. et al. Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals, Proc. Natl. Acad. Sci., 92, 8483, 1995.
156. Linton, M.F., Farese, R.V., and Young S.G. Familial hypobetalipoproteinemia, J. Lipid Res., 34, 521, 1993.
157. Schonfeld, G., Lin, X., and Yue, P. Familial hypobetalipoproteinemia: genetics and metabolism, Cell Mol. Life Sci., 62, 1372, 2005.
158. Yue, P. et al. Absence of fatty liver in familial hypobetalipoproteinemia linked to Chromosome 3p21, Metabolism, 54, 682, 2005.
159. Sankatsing, R.R. et al. Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia, Arterioscler. Thromb. Vasc. Biol. 25, 1979, 2005.
160. Tarugi, P. et al. Phenotypic expression of familial hypobetalipoproteinemia in three kindreds with mutations of the apolipoprotein B gene, J. Lipid Res., 42, 1552, 2001.
161. Neuman, R.J. et al. Replication of linkage of familial hypobetalipoproteinemia to Chromose 3p in six kindreds, J. Lipid Res., 43, 407, 2002.
162. Kim, T.W. et al. ISIS 326358, an antisense oligonucleotide targeted to apoB reduced plasma LDL-C in a monkey model of hyperlipidemia, Toxicologist, 90, 63, 2006.
163. Lin, X. et al. Hepatic fatty acid synthesis is suppressed in mice with fatty livers due to targeted apolipoprotein B38.9 mutation, Arterioscler. Thromb. Vasc. Bio., 22, 476, 2002.
164. Chen, Z. et al. Hepatic secretion of apoB-100 is impaired in hypobetalipoproteinemic mice with an apoB38.9-specifying allele, J. Lipid Res., 45, 155, 2004.
165. Chandler, C.E. et al. CP-356086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans, J. Lipid Res., 44, 1887, 2003.
166. Hardie, D.G. Minireview: The AMP-activated protein kinase cascade; the key sensor of cellular energy status, Endocrinology, 144, 5179, 2003.
167. Lin, H.Z. et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice, Nat. Med., 6, 998, 2000.
168. Zhou, G. et al. AMP-activated protein kinase in mechanism of metformin action, J. Clin. Invest., 108, 1167, 2001.
169. Lemonidis, et al. Pharmacological profiling of apolipoprotein B-100 and microsomal triglyceride transfer protein antisense inhibitors in hyperlipidemic mice, in 7th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology, Denver, April 27-29, 2006, P45.
170. Subramaniam, A., unpublished data, 2006.
171. Crooke, R.M., A human apolipoprotein B antisense inhibitor reduces aortic sinus plaque volume in LDL receptor-deficient apolipoprotein B-100 transgenic mice, in 7th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology, Denver, April 27-29, 2006, session A4.
172. Krieg, A.M. Immune stimulation by oligonucleotides, in Antisense Drug Technology. Principles, Strategies, and Applications, Crooke, S.T., ed., Marcel Dekker, Inc., New York, 2001, chap. 17.
173. Nawrocki, J.W. et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor, Arterioscler. Thromb. Vasc. Biol., 15,678, 1995.
174. Gottlieb, A.B. et al. Etanercept monotherapy in patients with psoriasis: a summary of safety based on an integrated multistudy database, J. Am. Acad. Dermatol., 54 (3 Suppl.2), S92, 2006.
175. Wedel, M., unpublished data, 2006.
176. Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs, Nature, 432, 172, 2004.
177. Henry, S.P. et al. Toxicological properties of several oligonucleotide analogs in mice, Anti-Cancer Drug Design, 12, 1, 1997.
178. Zimmerman, T.S. et al. RNAi-mediated gene silencing in non-human primates, Nature, 441, 111, 2006.
179. Yeh, E.T.H. and Willerson, J.T. Coming of age of C-reactive protein, Circulation, 107, 370, 2003.
180. Yeh, E.T.H. A new perspective on the biology of C-reactive protein, Circ. Res., 97, 609, 2005.
181. Verma, S., Szmitko, P.E., and Ridker, P.M. C-reactive protein comes of age, Nature Clinical Practice, 2, 29, 2005.
182. Agrawal, A., Kilpatrick, J.M., and Volanakis, J.E. Structure and Function of human C-reactive protein, in Acute phase proteins, Molecular biology, biochemistry, and clinical applications, Mackiewicz, A., Kushner, I., and Baumann, eds. CRC press, 1993, Boca Raton, Fl, chap. 4.
183. Ablij, H.C. and Meinders, A.E. C-reactive protein; history and revival, Europ. J. Int. Med., 13, 412, 2002.
184. Kushner, I., Rzewnicki, D., and Samols, D. What does minor elevation of C-reactive protein signify? Am. J. Med., 119, 166.e17, 2006.
185. Ridker, P.M. and Rifai, N. C-reactive protein in the primary prevention of myocardial infarction and stroke, in C-reactive Protein and Cardiovascular Disease, Ridker, P.M. and Rifai, N., eds., MediEdition, 2006, chap. 1.
186. Jialal, I., Devaraj, S., and Venugopal, S.K. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension, 44, 6, 2004.
187. Lagrand, W.K. et al. C-reactive protein as a cardiovascular risk factor. More than an epiphenomenon? Circulation, 100, 96, 1999.
188. Scirica, B.M. and Morrow, D.A. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out, Circulation, 113, 2128, 2006.
189. Verma, S., Devaraj, S., and Jialal, I. C-Reactive protein promotes atherothrombosis, Circulation, 113, 2135, 2006.
190. Wolbink, G.J. et al. CRP-mediated activation of complement in vivo. Assessment by measuring circulating complement-C-reactive protein complexes, J. Immunol., 157, 473, 1996.
191. Torzewski, J. et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries, Arterioscler. Thromb. Vasc. Biol., 18, 1386, 1998.
192. Shang-Rong, J. et al. Effect of modified C-reactive protein on complement activation. A possible complement regulatory role of modified or monomeric C-reactive protein in atherosclerotic lesions, Arterioscler. Thromb. Vasc. Biol., 26, 935, 2006.
193. Yasojima, K. et al. Generation of C-reactive protein and complement components in atherosclerotic plaques, Am. J. Pathol., 158, 1039, 2001.
194. Bisoedial, R.J. et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans, Circ. Res., 96, 714, 2005.
195. Pepys, M.B. et al. Targeting C-reactive protein for the treatment of cardiovascular disease, Nature, 440, 1217, 2006.
196. Crooke, R.M., Development of a human C-reactive protein antisense inhibitor, in Cytokines and Inflammation, GTCBios’s Fourth Annual Conference, San Diego, January 30-31, 2006.
197. Szalai, A.J. and McCrory, M.A. Varied functions of C-reactive protein: lesions learned from transgenic mice, Immunol. Res., 26, 279, 2002.
198. Danenberg, H.D. et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice, Circulation, 108, 512, 2003.
199. Wang, D. et al. Estrogen treatment abrogates neointima formation in human C-reactive protein transgenic mice, Arterioscler. Thromb. Vasc. Biol., 25, 2094, 2005.
200. Paul, A. et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice, Circulation, 109, 647, 2004.
201. Crooke, R.M., and Szalai, A., personal communication, 2006.
202. Hunt, S.C. and Hopkins, P.N., Hypertension genetics and mechanisms, in Atherothrombosis and Coronary Artery Disease, Fuster, V., Topol, E.J., and Nabel, E.G., eds., Lippincott, Williams and Wilkins, Philadelphia, 2005, chap. 13.
203. Frohlich, E.D., Clinical classifications of hypertensive disease, in Atherothrombosis and Coronary Artery Disease, Fuster, V., Topol, E.J., and Nabel, E.G., eds., Lippincott, Williams and Wilkins, Philadelphia, 2005, chap. 15.
204. Raizada, M.K. and Sarkissian, S.D. Potential of gene therapy strategy for the treatment of hypertension, Hypertension, 47, 6, 2006.
205. Jackson, E.K., Renin and angiotensin, in Goodman and Gilman’s The Pharmacological Basis of Therapeutics, Brunton, L.L., ed., McGraw-Hill, New York, 2006, chap. 30.
206. Phillips, M.I., and Kimura, B., Gene therapy for hypertension. Antisense inhibition of the reninangiotensin system, in Methods in Molecular Medicine, vol. 108: Hypertension: Methods and Protocols, Fennell, J.P. and Bake, A.H., eds., Humana Press, Inc., Totowa, N.J., 2005, 363.
207. Yoneda, M. et al. Differential effects of angiotensin II type-I receptor antisense oligonucleotides on renal function in spontaneously hypertensive rats, Hypertension, 46, 58, 2005.
208. Pachori, A.S. et al. The future of hypertension therapy: Sense, antisense, or nonsense? Hypertension, 37 (part 2), 357, 2001.
209. Tomita, N. and Morishita, R. Antisense oligonucleotides as a powerful molecular strategy for gene therapy in cardiovascular disease, Curr. Pharmaceut. Des., 10, 797, 2004.
210. Phillips. M.I. and Kimura, B.C. Brain angiotensin in the developing spontaneously hypertensive rat, J. Hypertension, 6, 607, 1088.
211. Kagiyama, S. et al. Antisense inhibition of brain renin-angiotensin system decreased blood pressure in chronic 2-kidney, 1 clip hypertensive rats, Hypertension, 37, 371, 2001.
212. Peng, J.-F. et al. Reduction of cold-induced hypertension by antisense oligodeoxynucleotides to angiotensinogen mRNA and AT1-receptor mRNA in brain and blood, Hypertension, 31, 1317, 1998.
213. Sinnayah, P. et al. Selective gene transfer to key cardiovascular regions of the brain: Comparison of two viral vector systems, Hypertension, 39 (part 2), 603, 2002.
214. Gardon, M.L. et al. The potential use of gene therapy in the control of hypertension, Drugs Today, 35, 92,225, 1999.
215. Serruys, P.W., Kutryk, M.J., and Ong, A.T. Coronary-artery stents. N. Engl. J.Med., 354, 483, 2006.
216. Costa, M.A. and Simon, D.I. Molecular basis of restenosis and drug-eluting stents. Circulation, 111, 2257, 2005.
217. Monia, B.P. and Dean, N.M. Pharmacological activity of antisense oligonucleotides in animal models of disease, in Antisense Research and Application, Crooke, S.T., ed., Springer-Verlag, Berlin, 1998, chap. 14.
218. Kipshidze, N. et al. Antisense therapy for restenosis following percutaneous coronary intervention, Expert. Opin. Biol. Ther., 5, 79, 2005.
219. Abe, J. et al. Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery, Biochem. Biophys. Res. Comm., 198, 16, 1994.
220. Simons, M. et al. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo, Nature, 359, 67, 1992.
221. Burgess, T.L. et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism, Proc. Natl., Acad., Sci., 92, 4051, 1995.
222. Morishita, R. et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia, Proc. Natl., Acad., Sci., 90, 8474, 1993.
223. Cohen-Sacks, H. et al. Novel PDGFBR antisense encapsulated in polymeric nanospheres for the treatment of restenosis, Gene Therapy, 9, 1607, 2002.
224. Kipshidze, N. et al. Complete vascular healing and sustained suppression of neointimal thickening after local delivery of advance c-myc antisense at six months follow-up in a rabbit balloon injury model, Cardiovasc. Radiat. Med., 3, 26, 2002.
225. Kutryk, M.J. et al. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial, J. Am. Coll. Cardiol., 39, 281, 2002.
226. Iversen, P.L. et al. Local application of antisense for prevention of restenosis, Methods Mol. Med., 106, 37, 2005.